BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26546509)

  • 1. A case series of anal melanoma including the results of treatment with imatinib in selected patients.
    Knowles J; Lynch AC; Warrier SK; Henderson M; Heriot AG
    Colorectal Dis; 2016 Sep; 18(9):877-82. PubMed ID: 26546509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
    Schaefer T; Satzger I; Gutzmer R
    Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
    Quintás-Cardama A; Lazar AJ; Woodman SE; Kim K; Ross M; Hwu P
    Nat Clin Pract Oncol; 2008 Dec; 5(12):737-40. PubMed ID: 18936790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
    Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
    Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignancies of the anal canal: a multi-center retrospective analysis in South China population.
    Sun P; Li YH; Wang W; Chen CQ; Wang LY
    J BUON; 2014; 19(1):103-8. PubMed ID: 24659650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study.
    Wei X; Mao L; Chi Z; Sheng X; Cui C; Kong Y; Dai J; Wang X; Li S; Tang B; Lian B; Yan X; Bai X; Zhou L; Guo J; Si L
    Oncol Res; 2019 Mar; 27(4):495-501. PubMed ID: 30075827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
    Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
    Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma of the anal canal: a case series.
    Homsi J; Garrett C
    Dis Colon Rectum; 2007 Jul; 50(7):1004-10. PubMed ID: 17468984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.
    Schiller DE; Cummings BJ; Rai S; Le LW; Last L; Davey P; Easson A; Smith AJ; Swallow CJ
    Ann Surg Oncol; 2007 Oct; 14(10):2780-9. PubMed ID: 17638059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
    Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
    Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
    Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
    J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anorectal malignant melanoma: retrospective analysis of management and outcome in a single Portuguese Institution.
    Miguel I; Freire J; Passos MJ; Moreira A
    Med Oncol; 2015 Jan; 32(1):445. PubMed ID: 25502089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing local control in anorectal melanoma.
    Ramakrishnan AS; Mahajan V; Kannan R
    Indian J Cancer; 2008; 45(1):13-9. PubMed ID: 18453735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anal carcinoma or "just hemorrhoids"?
    Winburn GB
    Am Surg; 2001 Nov; 67(11):1048-58. PubMed ID: 11730221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database.
    Kiran RP; Rottoli M; Pokala N; Fazio VW
    Dis Colon Rectum; 2010 Apr; 53(4):402-8. PubMed ID: 20305438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Care and Survival Outcomes in the Treatment of Anal Melanoma.
    Naqvi J; Lee A; Lederman A; Kavi A; Osborn VW; Schreiber D
    J Gastrointest Cancer; 2020 Mar; 51(1):211-216. PubMed ID: 30982929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival following salvage abdominoperineal resection for persistent and recurrent squamous cell carcinoma of the anus: do these disease categories affect survival?
    Severino NP; Chadi SA; Rosen L; Coiro S; Choman E; Berho M; Wexner SD
    Colorectal Dis; 2016 Oct; 18(10):959-966. PubMed ID: 26850085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
    Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
    Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Case of Gastrointestinal Stromal Tumor(GIST)Originating in the Anal Canal].
    Terada I; Yoshikawa A; Maruzen S; Yagi Y; Sasaki S; Fukushima W; Kitagawa H; Fujimura T; Izumi R
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2453-2455. PubMed ID: 28133352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.